Delgocitinib

Delgocitinib
Clinical data
Trade names	Corectim, others
Other names	JTE-052; JTE-052A
ATC code	D11AH11 (WHO) ;
Legal status
Legal status	EU: Rx-only; JP: Rx-only;
Identifiers
	IUPAC name 3-[(3S,4R)-3-Methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile;
CAS Number	1263774-59-9;
PubChem CID	50914062;
DrugBank	DB16133;
ChemSpider	59718502;
UNII	9L0Q8KK220;
KEGG	D11046;
CompTox Dashboard (EPA)	DTXSID401336933 ;
Chemical and physical data
Formula	C16H18N6O
Molar mass	310.361 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2;
	InChI InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1; Key:LOWWYYZBZNSPDT-ZBEGNZNMSA-N;

Delgocitinib, sold under the brand name Corectim among others, is a medication used for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions.^[3] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis.^[3] In the United States, delgocitinib is in Phase III clinical trials and the Food and Drug Administration has granted delgocitinib fast track designation for topical treatment of adults with moderate to severe chronic hand eczema.^[4]

Delgocitinib works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases.^[5]

Society and culture

Legal status

In July 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Anzupgo, intended for the treatment of chronic hand eczema.^[1]^[6] The applicant for this medicinal product is LEO Pharma A/S.^[1] Anzupgo was approved for medical use in the European Union in September 2024.^[1]

References

^ ^a ^b ^c ^d "Anzupgo EPAR". European Medicines Agency. 25 July 2024. Retrieved 25 July 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ "Anzupgo PI". Union Register of medicinal products. 23 September 2024. Retrieved 27 September 2024.
^ ^a ^b Dhillon S (April 2020). "Delgocitinib: First Approval". Drugs. 80 (6): 609–615. doi:10.1007/s40265-020-01291-2. PMID 32166597. S2CID 212681247.
^ Park B (5 August 2020). "Delgocitinib Cream Gets Fast Track Status for Chronic Hand Eczema". empr.com.
^ Szalus K, Trzeciak M, Nowicki RJ (November 2020). "JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results". Microorganisms. 8 (11): 1743. doi:10.3390/microorganisms8111743. PMC 7694787. PMID 33172122.
^ "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024". European Medicines Agency (Press release). 25 July 2024. Retrieved 29 July 2024.

[Anzupgo_EPAR-1] "Anzupgo EPAR". European Medicines Agency. 25 July 2024. Retrieved 25 July 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[2] "Anzupgo PI". Union Register of medicinal products. 23 September 2024. Retrieved 27 September 2024.

[Dhillon-3] Dhillon S (April 2020). "Delgocitinib: First Approval". Drugs. 80 (6): 609–615. doi:10.1007/s40265-020-01291-2. PMID 32166597. S2CID 212681247.

[4] Park B (5 August 2020). "Delgocitinib Cream Gets Fast Track Status for Chronic Hand Eczema". empr.com.

[5] Szalus K, Trzeciak M, Nowicki RJ (November 2020). "JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results". Microorganisms. 8 (11): 1743. doi:10.3390/microorganisms8111743. PMC 7694787. PMID 33172122.

[6] "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024". European Medicines Agency (Press release). 25 July 2024. Retrieved 29 July 2024.

[1]

[2]

[3]

[4]

[5]

[6]